APMD

Apnimed, Inc.
CAPPED RATING

Apnimed, Inc. (APMD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A+); its weakest is Growth (D-). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
D-
Factor Score 0.7 / 5.0
Profitability
A+
Factor Score 4.8 / 5.0
Momentum
D
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.3
EV / EBITDA 24.2
Rev Growth YoY -29.4%
Gross Margin 93.9%
Price Return 3M -48.8%
Price Return 12M -34.9%
Catalyst Signal 0.00
Market Cap $677.7M
TTM Revenue $115.1M
Price / Sales 5.9
ROE N/A

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) D- (0.7) A+ (4.8) D (1.5) C+ (2.6) C+ (2.5)
2026-11-10 B- (3.0) F (0.7) A+ (4.8) D+ (1.8) C+ (2.6) C+ (2.6)
2026-11-03 B- (3.0) F (0.7) A+ (4.8) C- (1.9) C+ (2.7) C+ (2.6)
2026-10-27 B- (2.9) F (0.7) A+ (4.8) C- (2.0) C+ (2.6) C+ (2.6)
2026-10-20 B- (3.0) F (0.7) A+ (4.8) C (2.5) C+ (2.6) C+ (2.7)
Page 1 of 4